New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2012
10:00 EDTSRPT, SMBL, BP, ATRS, RLGY, SNDK, DNKN, LNCO, Z, RDS.A, AAPLOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Apple (AAPL) initiated with a Buy at Citigroup... BP (BP) initiated with an Outperform at Exane BNP Paribas... Dunkin' Brands (DNKN) initiated with a Buy at UBS... Royal Dutch Shell (RDS.A) initiated with an Underperform at Exane BNP Paribas... SanDisk (SNDK) initiated with an Outperform at Credit Suisse... Silicon Laboratories (SLAB) initiated with an Outperform at Pacific Crest... Smart Balance (SMBL) initiated with a Top Pick at RBC Capital... Zillow (Z) initiated with an Equal Weight at Morgan Stanley... Sarepta (SRPT) initiated with an Outperform at Burrill... Realogy (RLGY) initiated with a Buy at CRT Capital... LinnCo (LNCO) initiated with a Strong Buy at Raymond James... Antares Pharma (ATRS) initiated with a Buy at Guggenheim.
News For A;SNDK;SMBL;Z;RLGY;SRPT;LNCO;ATRS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 21, 2015
10:01 EDTSRPTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:59 EDTSRPTSarepta downgraded to Neutral from Outperform at Wedbush
Subscribe for More Information
January 20, 2015
07:17 EDTSNDKSanDisk downgraded to Reduce from Neutral at Nomura
Subscribe for More Information
January 16, 2015
16:36 EDTSNDKMarket finishes week lower on continued oil, global growth worries
Subscribe for More Information
14:29 EDTSNDKSanDisk January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
10:20 EDTATRSAntares Pharma management to meet with JMP Securities
Subscribe for More Information
January 15, 2015
15:26 EDTSRPTSarepta says no safety info or comparison in BioMarin presentation
Sarepta (SRPT) said that, given the small sample size of study 201/202, the company understood the importance of providing an "extensive amount of date" in order to understand eteplirsen's treatment effect. Sarepta has reported mITT data since week 24 and has continued to provide updates on this same mITT at every timepoint, the company said. BioMarin's (BMRN) presentation on Monday focused on extension phase and excluded dose-escalation phase and results during off-treatment periods, according to Sarepta. "Sarepta has regularly reported complete 201/202 safety data on all patients. No safety information or comparison [was included] in BioMarin's Monday presentation," Sarepta wrote in slides for its presentation at the JPMorgan Healthcare Conference.
09:29 EDTSNDKNetlist claim against Diablo controller chips upheld
Netlist (NLST) announced that the U.S. District Court for the Northern District of California denied a motion filed by Diablo Technologies on January 13 requesting the Court to stay the Preliminary Injunction against controller chips used by SanDisk (SNDK) in its high-speed ULLtraDIMM SSD product line. The Preliminary Injunction will therefore remain in place. The Court in a separate ruling rejected SanDisk's request that it be allowed to sell existing inventory of the enjoined products. This order made clear that Diablo and SanDisk are working in concert and are now prohibited from manufacturing and selling the Diablo controller chipset used in the ULLtraDIMM and as a result, from further sale or distribution by SanDisk of the ULLtraDIMM itself.
07:13 EDTSRPTJPMorgan to hold a conference
Subscribe for More Information
January 14, 2015
08:30 EDTSRPTSarepta says first patient dosed in European Phase 1/II SRP-4053 study
Subscribe for More Information
08:00 EDTSNDKSanDisk weakness likely temporary, says Bernstein
Subscribe for More Information
January 13, 2015
10:00 EDTSNDKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:07 EDTATRSOn The Fly: Pre-market Movers
HIGHER: Apple (AAPL), up 1.4% after Credit Suisse upgraded Apple to Outperform and raised its iPhone volume estimates again... Best Buy (BBY), up 2.8% after being upgraded to Buy from Neutral at Goldman... SunPower (SPWR), up 2.6% after being upgraded to Outperform at Credit Suisse... Alcoa (AA), up 2% after Q4 results beat expectations. RISING AFTER GUIDANCE: Pharmacyclics (PCYC), up 17.5%... CTI BioPharma (CTIC), up 8.3%... Emulex (ELX), up 15.5%... ARIAD (ARIA), up 2.6%. LOWER: ChannelAdvisor (ECOM), down 42% following preliminary fourth quarter revenue guidance and after receiving multiple analyst downgrades... Antares Pharma (ATRS), down 7.7% after the FDA recommended that the company create a larger safety database for its clinical development program for QuickShot Testosterone.
08:53 EDTSNDKSanDisk downgraded to Hold from Buy at Drexel Hamilton
Subscribe for More Information
08:17 EDTSNDKSanDisk price target lowered to $100 from $110 at UBS
Subscribe for More Information
07:08 EDTATRSAntares Pharma receives written recommendations from FDA on QuickShot
Antares Pharma announced that it has received written recommendations from the FDA related to its clinical development program for QuickShot Testosterone, or QS T. The recommendations received were in response to various clinical, Chemistry, Manufacturing and Controls and user study submissions made by the company through November 2014. The company believes that it has already factored many of the recommendations cited in the advice letter into the protocol of the ongoing phase 3 study and into the protocols for planned human use studies as a result of guidance provided by FDA at the May 2014 Type C meeting. Based on a single reported occurrence of hives in the company’s phase 2 study, which the FDA characterized as an apparent allergic reaction, as well as the known safety experience with other parenteral testosterone products, the FDA is recommending that the company create a larger safety database, including approximately 350 subjects exposed to QS T with 200 subjects exposed for six months and 100 subjects exposed for a year. The company does not believe that the adverse event of hives reported in the phase 2 study was related to study drug. Based on the number of subjects in previous studies and in the current phase 3 study, the company anticipates that it may need approximately 70 additional subjects exposed to QS T for six months. The company is assessing the FDA’s comments in the advice letter and their impact on the timing of the filing of a New Drug Application for QS T with the FDA. The timing, cost and design of the study to obtain the additional 70 subjects and data required will be determined based on further discussion with the FDA. The company continues to expect to release top-line pharmacokinetic data from the current phase 3 study in the second quarter of 2015.
07:07 EDTSNDKSanDisk shares should be bought on weakness, says Pacific Crest
Subscribe for More Information
07:04 EDTSNDKFederal court confirms halt to sales of chips used by SanDisk, IBM, others
Subscribe for More Information
06:30 EDTSNDKCourt order bars sales of chips used by SanDisk and IBM, WSJ reports
Subscribe for More Information
06:29 EDTSNDKSanDisk pullback yesterday looks overdone, says Citigroup
Citigroup believes the 14% pullback yesterday in shares of SanDisk following the company's Q4 guide-down looks overdone. Citi views the cause of the shortfall as temporary cyclical factor that it thinks should alleviate with the release of the Samsung S6 in March. It dropped its price target for the stock to $110 from $125 but keeps a Buy rating on the name.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use